Updates on the Management of CINV From the 2014 June Congresses

Program Goals

Introduction

Introduction (cont)

3 Major Classes of Antiemetic Agents Used in CINV Prevention

Antiemetic Guidelines: Current Recommendations

NK-1 RAs: Aprepitant

Investigational NK-1 RAs

Investigational NK-1 RAs (cont)

Aprepitant vs Metoclopromide in Delayed CINV

Rolapitant in Patients Receiving MEC Phase 3 Study Design

Rolapitant in Patients Receiving MEC Efficacy Results

Rolapitant in Patients Receiving MEC Safety

Rolapitant in Patients Receiving HEC Study Design of 2 Phase 3 RCTs

Rolapitant in Patients Receiving HEC Efficacy Results

NEPA: A Fixed Dose Oral Combination of Netupitant and Palonosetron Primary End Point Efficacy Results From 3 RCTs

NEPA + DEX vs Oral PALO + DEX in AC-based MEC Multinational, Randomized, Double-blind Phase 3 Study

NEPA + DEX vs Oral PALO + DEX in AC-based MEC Overall CR Rates Across Multiple Cycles

NEPA + DEX vs PALO + DEX in AC-Based MEC Safety Across Multiple Cycles

NEPA + DEX vs PALO + DEX in AC-based MEC Most Common TRAEs Across Multiple Cycles

Non-AC MEC

NEPA in Multicycle MEC and HEC Phase 3 Study Design

NEPA in Multicycle MEC and HEC Patient Baseline and Disease Characteristics

NEPA in Multicycle MEC and HEC Post-Hoc Analysis of No Emesis Rates (Cycle 1) in Patients Receiving Carboplatin

Fosaprepitant in Non-AC MEC Phase 3 Study Design

APF530 vs Palonosetron

Aprepitant in Pediatric Patients Phase 3 Study Design

The Problem of Nausea

Summary

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)